Journal
JAMA ONCOLOGY
Volume 8, Issue 3, Pages 335-336Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jamaoncol.2021.6854
Keywords
-
Categories
Ask authors/readers for more resources
This viewpoint compares the US FDA's accelerated approval pathway for drugs and biologics with similar programs developed by other international regulatory health authorities.
This Viewpoint compares the US Food and Drug Administration's accelerated approval pathway for drugs and biologics with similar programs developed by other international regulatory health authorities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available